Field Safety Notices: 3 to 7 January 2022
A weekly index of the field safety notices manufacturers issued that week.
Source · Drug & device safety alerts
MHRA Drug & Device Safety Alerts
1,501 individual alerts
447 medicines recalls & defect notices
766 weekly / monthly index pages
Oct 2009 – Jul 2026
Drug safety updates, medicines recalls, device safety information and field safety notices published by the Medicines and Healthcare products Regulatory Agency. Source: MHRA alerts and recalls on GOV.UK.
Showing 2,267 publications of 2,267
Field Safety Notices: 29 to 31 December 2021
A weekly index of the field safety notices manufacturers issued that week.
Company led medicines recall: Dermaved Sensitive Cream (unlicensed medicine), CLMR (21)A/09
A recall the marketing authorisation holder initiated, published by MHRA.
Field Safety Notices: 20 to 24 December 2021
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines defect information: Benylin Chesty Coughs Original (P) and Benylin Chesty Coughs Non-Drowsy (GSL), EL(21)A/39
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 13 to 17 December 2021
A weekly index of the field safety notices manufacturers issued that week.
Rheovalves disposable needle-free valves: stop using specific lots due to risk of breakage in patient. DSI/2021/010
Class 2 Medicines Recall: Wockhardt UK Ltd, Heparin sodium 1,000 I.U./ml solution for injection or concentrate for solution for infusion, EL (21)A/38
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Class 4 Medicines Defect Information: SmofKabiven Central emulsion for Infusion, Fresenius Kabi Ltd, EL (21)A/37
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 6 to 10 December 2021
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Novartis Pharmaceuticals UK, Lucentis 10 mg/ml solution for injection in pre-filled syringe EL (21)A/36
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
COVID-19 vaccines and medicines: updates for December 2021
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in November 2021
A periodic index page listing other alerts and letters, not a single alert.
Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)
An article in MHRA's monthly Drug Safety Update bulletin.
Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
An article in MHRA's monthly Drug Safety Update bulletin.
Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus
An article in MHRA's monthly Drug Safety Update bulletin.
Class 2 Medicines Recall: Intrapharm Laboratories Ltd, Mydrilate 0.5% Eye Drops 5ml, EL (21)A/35
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 29 November to 3 December 2021
A weekly index of the field safety notices manufacturers issued that week.
Medical device alerts archived in December 2021
A periodic index page listing other alerts and letters, not a single alert.
Field Safety Notices: 22 to 26 November 2021
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Diuril Oral Solution (unlicensed medicine), Mawdsley-Brooks & Company Limited, EL (21)A/32
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 4 Medicines Defect Information: Mometasone Furoate 50 Microgram / Dose Nasal Spray, Suspension, PilsCo Ltd, EL (21)A/33
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 15 to 19 November 2021
A weekly index of the field safety notices manufacturers issued that week.
Handpieces used in the phacoemulsification technique of cataract removal: need for careful cleaning (DSI/2021/009)
Device Safety Information (DSI): MHRA advice on a device already in use.
Class 3 Medicines Recall: Martindale Pharma, an Ethypharm Group Company Methadone 5mg Tablets / Physeptone 5mg Tablets, EL (21)A/31
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Class 2 Medicines Recall: SANTEN Oy (trading as Santen UK Limited) and parallel distributor, IKERVIS 1 mg/mL eye drops, emulsion and VERKAZIA 1 mg/mL eye drops, emulsion, EL (21)A/30
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Company led medicines recall: Dotarem solution for injection (10ml Vial) - PL 12308/0016
A recall the marketing authorisation holder initiated, published by MHRA.
COVID-19 vaccines and medicines: updates for November 2021
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in October 2021
A periodic index page listing other alerts and letters, not a single alert.
Yellow fever vaccine (Stamaril): new pre-vaccination checklist
An article in MHRA's monthly Drug Safety Update bulletin.
Adrenaline auto-injectors: reminder for prescribers to support safe and effective use
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notices: 8 to 12 November 2021
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Slenyto 1 mg and 5mg prolonged-release tablets – distributed by Flynn Pharma Ltd, EL (21)A/29
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 2 Medicines Recall: Cold & Flu Relief Capsules (GSL) – Various Liveries, Wrafton Laboratories Limited (trading as Perrigo), EL (21)A/28
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Medical device alerts archived in November 2021
A periodic index page listing other alerts and letters, not a single alert.
Class 4 Medicines Defect Information: Vygoris Limited, Mitocin (mitomycin) 20mg powder for solution for injection/infusion or intravesical use, EL (21)A/27
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 1 to 5 November 2021
A weekly index of the field safety notices manufacturers issued that week.
UPDATE: Class 4 Medicines Defect Information: Crescent Pharma Ltd, SyreniRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system, EL (20)A/36
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 25 to 29 October 2021
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Bimatoprost Aspire 0.3mg/ml eye drops, solution in single-dose container, Aspire Pharma Limited, EL (21)A/26
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Field Safety Notices: 18 to 22 October 2021
A weekly index of the field safety notices manufacturers issued that week.
Company led medicines recall: Irinotecan 200mg/ 260mL in sodium chloride 0.9% w/v intravenous infusion and Infliximab (Remsima) intravenous infusion in sodium chloride 0.9%
A recall the marketing authorisation holder initiated, published by MHRA.
Class 2 Medicines Recall: Pfizer Ltd, Champix (all strengths) film-coated tablets, EL (21)A/25
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Class 2 Medicines Recall: Tesco Flu-Max All In One Chesty Cough & Cold Powder for Oral Solution Wrafton Laboratoires Limited (trading as Perrigo) EL (21)A/24
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Medical device alerts archived in October 2021
A periodic index page listing other alerts and letters, not a single alert.
MedSafetyWeek November 2021: support the safety of vaccines
An article in MHRA's monthly Drug Safety Update bulletin.
COVID-19 vaccines: updates for October 2021
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in September 2021
A periodic index page listing other alerts and letters, not a single alert.
Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies
An article in MHRA's monthly Drug Safety Update bulletin.
Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication
An article in MHRA's monthly Drug Safety Update bulletin.
About this source
Individual alerts by type
Read the chart values
| Alert type | Individual alerts |
|---|---|
| Drug Safety Update | 713 |
| Class 1 Medicines Recall | 6 |
| Class 2 Medicines Recall | 159 |
| Class 3 Medicines Recall | 68 |
| Class 4 Medicines Defect Information | 179 |
| Company-Led Medicines Recall | 35 |
| Device Safety Information | 21 |
| Medical Device Alert | 40 |
| National Patient Safety Alert | 11 |
| MHRA Safety Roundup | 16 |
| Unclassified | 253 |
The MHRA regulates medicines and medical devices in the UK and publishes safety communications on GOV.UK in two streams: the monthly Drug Safety Update bulletin, and Alerts and recalls for drugs and medical devices. This page holds 2,267 of those publications, issued between October 2009 and July 2026.
MHRA classes a medicines recall by the hazard the defect presents: Class 1 life-threatening or serious, Class 2 could cause illness or mistreatment, Class 3 unlikely to cause harm, and Class 4 a caution in use rather than a recall, with the product staying available. A device notice is published as Device Safety Information, or, until 2021, as a Medical Device Alert.
What is not here. We hold each publication's title, type, date and link, not its text: read the alert on GOV.UK for the affected products and the actions MHRA asks for. An alert names a medicine or device and a clinical audience, not an organisation, so no alert on this page is linked to an NHS trust or other responsible body. The weekly “Field Safety Notices” pages are MHRA's own index of the notices manufacturers issued that week, not single alerts, and are counted separately above.